company background image
ALIM logo

Alimera Sciences NasdaqGM:ALIM Stock Report

Last Price

US$3.90

Market Cap

US$204.2m

7D

-3.0%

1Y

119.1%

Updated

28 Mar, 2024

Data

Company Financials +

Alimera Sciences, Inc.

NasdaqGM:ALIM Stock Report

Market Cap: US$204.2m

ALIM Stock Overview

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals.

ALIM fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Alimera Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Alimera Sciences
Historical stock prices
Current Share PriceUS$3.90
52 Week HighUS$4.38
52 Week LowUS$1.56
Beta1.16
1 Month Change11.43%
3 Month Change-9.72%
1 Year Change119.10%
3 Year Change-60.45%
5 Year Change-73.74%
Change since IPO-97.64%

Recent News & Updates

Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Feb 15
Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Recent updates

Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Feb 15
Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?

Dec 30
Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?

Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)

Oct 13
Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Sep 13
Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data

Oct 06

Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland

Sep 20

Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection

Aug 09

Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection

Jul 22

Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation

Jul 08

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Mar 24
Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?

Nov 06
Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?

Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Aug 24
Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares

Feb 11
Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares

Alimera Sciences (ALIM) Investor Presentation - Slideshow

Nov 18

Shareholder Returns

ALIMUS PharmaceuticalsUS Market
7D-3.0%2.2%0.2%
1Y119.1%25.5%28.1%

Return vs Industry: ALIM exceeded the US Pharmaceuticals industry which returned 25.8% over the past year.

Return vs Market: ALIM exceeded the US Market which returned 28.8% over the past year.

Price Volatility

Is ALIM's price volatile compared to industry and market?
ALIM volatility
ALIM Average Weekly Movement7.6%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: ALIM has not had significant price volatility in the past 3 months.

Volatility Over Time: ALIM's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003157Rick Eiswirthhttps://alimerasciences.com

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).

Alimera Sciences, Inc. Fundamentals Summary

How do Alimera Sciences's earnings and revenue compare to its market cap?
ALIM fundamental statistics
Market capUS$204.18m
Earnings (TTM)-US$21.39m
Revenue (TTM)US$80.75m

2.5x

P/S Ratio

-9.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALIM income statement (TTM)
RevenueUS$80.75m
Cost of RevenueUS$10.84m
Gross ProfitUS$69.92m
Other ExpensesUS$91.31m
Earnings-US$21.39m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.41
Gross Margin86.58%
Net Profit Margin-26.49%
Debt/Equity Ratio139.7%

How did ALIM perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.